Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eurofins Genomics Launches SARS-CoV-2 Plasmid DNA Controls | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eurofins Genomics Launches SARS-CoV-2 Plasmid DNA Controls

Can be used to detect the presence of SARS-CoV-2 virus and are intended for both R&D and diagnostic applications.

By: Contract Pharma

Contract Pharma Staff

Eurofins Genomics U.S., together with its subsidiary BlueHeron Biotechnology, has launched a series of SARS-CoV-2 plasmid DNA controls that can be used to detect the presence of the SARS-CoV-2 virus. They are intended to be used for R&D and IVD diagnostic applications.

Eurofins Genomics U.S. offers three different COVID-19 controls targeting key segments of the 30,000 base SARS-CoV-2 genome. One of the positive controls, CVGP, covers a wide swath of the sequence so that users can set up multiple reactions under a single control. Eurofins Genomics U.S. is able to produce and ship the plasmid control within one day.

The company has also ramped up production of reverse transcription quantitative polymerase chain reaction (qPCR RT) dual-labeled probes and primers for commercial and molecular diagnostic companies producing their own test kits. Eurofins Genomics U.S. has been able to meet demand and delivery timelines due to its logistical position in a major courier hub as well as its synthesis technology. On average, Eurofins Genomics U.S. ships out qPCR assay panels in three days.

All material for SARS-CoV-2, both the qPCR RT probes and plasmid controls, are produced under ISO 13485 and ISO 9001 for IVD products. The company’s experience partnering with IVD kit producers in the past has allowed them to respond to the spike in demand for test kits.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics